PHARMACOLOGICAL MODULATION OF POLY(ADP-RIBOSE) METABOLISM
多聚(ADP-核糖)代谢的药理学调节
基本信息
- 批准号:9107059
- 负责人:
- 金额:$ 3.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-07 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingActive SitesAdenosine Diphosphate RiboseAffectBRCA1 geneBRCA2 geneBindingBinding SitesBiochemicalBiological AssayBiological AvailabilityBreast Cancer TreatmentCell DeathCell ExtractsCell LineCellsChemicalsChemotherapy-Oncologic ProcedureClinicalComplementCrystallizationCultured CellsDNA DamageDNA RepairDNA StructureDataDefectDiseaseDockingDoseDose-LimitingEnzymesExcisionGeneticGenomic InstabilityGenotypeGoalsHumanImmunodeficient MouseIn VitroKineticsLeadLibrariesLigand BindingLigandsMalignant NeoplasmsMalignant neoplasm of ovaryMammary NeoplasmsMetabolismMinorityModalityModificationMolecular ConformationMono-SMusMutationOralOutcomeOxidative StressPatientsPharmaceutical PreparationsPhenocopyPhenotypePhysiologicalPlasmaPoly Adenosine Diphosphate RibosePoly(ADP-ribose) PolymerasesPost-Translational Protein ProcessingProcessPropertyProteinsProtocols documentationRadiationResistanceRiboseRoleSiteStructureTestingTherapeuticToxic effectTransformed Cell LineTyrosineXanthinesXenograft Modelacute toxicityanalogbasecancer cellcancer therapychemical synthesischemosensitizing agentchemotherapydesignhigh throughput screeningimprovedin vitro testingin vivoinhibitor/antagonistkillingsknock-downmalignant breast neoplasmmembermethylxanthinenanomolarnew therapeutic targetovarian neoplasmpharmacophorepoly ADP-ribose glycohydrolasepoly ADPR glycohydrolase inhibpreclinical evaluationpreclinical trialpublic health relevancequantitative imagingreceptorresearch studyresponsescreeningsmall moleculesmall molecule librariessuccesstargeted cancer therapytargeted treatmenttherapy resistanttumortumor growthtumor xenograft
项目摘要
DESCRIPTION (provided by applicant) Molecularly-targeted cancer therapies have revolutionized the treatment of this heterogeneous and increasingly prevalent disease. Genetic instability is a hallmark of many cancers that generates mutations to support uncontrolled tumor growth and resistance to chemotherapies. The underlying DNA repair defects in these tumors can be exploited in tumor-selective therapies that block critical remaining DNA repair functions to trigger catastrophic damage and cell death. This idea is borne out by the clinical successes of inhibitors of poly(ADP-ribose) polymerase 1 (PARP1) to treat breast and ovarian cancers with mutations in BRCA1 or BRCA2. However, these BRCA-deficient tumors account for a minority of cancers so it is important to identify other physiological defects of tumors that are synthetically lethal in combination with molecularly targeted therapies. Additionally, the current PARP inhibitors suffer from dose-limiting toxicities, which may result from off-target effects on other members of the large PARP superfamily. As an alternative to PARP inhibitors, we used high-throughput screening to identify selective inhibitors of the human poly(ADP-ribose) glycohydrolase PARG. PARG is a monogenic enzyme that removes the poly(ADP-ribose) posttranslational modification of proteins modified by PARP1. A genetic knockdown of PARG sensitizes cancer cells to DNA damaging agents and radiation and phenocopies the tumor-specific killing effects of PARP1 enzymatic inhibitors in BRCA- deficient cancer cells. In this application, we propose experiments to improve the potency and selectivity of small molecule PARG inhibitors through structure-guided chemical synthesis and testing in vitro, and to advance selected compounds to preclinical trials of tumor killing activity in cultured cells and xenograft models of breast cancer. We will synthesize focused libraries of analogs that exploit unique features of the PARG active site and screen small molecule fragment library to identify new chemotypes and interactions that can be incorporated into our inhibitor design strategy. Selective inhibitors of PARG will be useful probes of cellular responses to cancer chemotherapeutics that damage DNA, and may be useful cancer therapies in their own right by exploiting the genomic instability phenotype of many tumors.
描述(由申请人提供)分子靶向癌症疗法已经彻底改变了这种异质性和日益普遍的疾病的治疗。遗传不稳定性是许多癌症的标志,这些癌症产生突变以支持不受控制的肿瘤生长和对化疗的抗性。这些肿瘤中潜在的DNA修复缺陷可以用于肿瘤选择性疗法,这些疗法可以阻止关键的剩余DNA修复功能,从而引发灾难性损伤和细胞死亡。这一想法得到了聚(ADP-核糖)聚合酶1(PARP 1)抑制剂治疗BRCA 1或BRCA 2突变的乳腺癌和卵巢癌的临床成功的证实。然而,这些BRCA缺陷型肿瘤仅占少数癌症,因此重要的是要确定与分子靶向治疗相结合的合成致死性肿瘤的其他生理缺陷。此外,目前的PARP抑制剂具有剂量限制性毒性,这可能是由于对大型PARP超家族其他成员的脱靶效应造成的。作为PARP抑制剂的替代品,我们使用高通量筛选来鉴定人聚(ADP-核糖)糖水解酶PARG的选择性抑制剂。PARG是一种单基因酶,其去除由PARP 1修饰的蛋白质的聚(ADP-核糖)翻译后修饰。PARG的基因敲低使癌细胞对DNA损伤剂和辐射敏感,并且表型模仿PARP 1酶抑制剂在BRCA缺陷癌细胞中的肿瘤特异性杀伤作用。在本申请中,我们提出了通过结构指导的化学合成和体外测试来提高小分子PARG抑制剂的效力和选择性的实验,并将选定的化合物推进到乳腺癌培养细胞和异种移植模型中的肿瘤杀伤活性的临床前试验。我们将合成利用PARG活性位点的独特特征的类似物的集中文库,并筛选小分子片段文库以鉴定可以纳入我们的抑制剂设计策略的新化学型和相互作用。PARG的选择性抑制剂将是对损伤DNA的癌症化疗剂的细胞应答的有用探针,并且通过利用许多肿瘤的基因组不稳定表型,其本身可能是有用的癌症疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TOM E. ELLENBERGER其他文献
TOM E. ELLENBERGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TOM E. ELLENBERGER', 18)}}的其他基金
MACCHESS FOR PHASING METHODS IN MACROMOLECULAR CRYSTALS
用于大分子晶体定相方法的 MACCHESS
- 批准号:
6977223 - 财政年份:2004
- 资助金额:
$ 3.89万 - 项目类别:
MACCHESS CONSORTIUM FOR PHASING METHODS IN MACROMOLECULAR CRYSTALLOGRAPHY
MACCHESS 高分子晶体学定相方法联盟
- 批准号:
6667793 - 财政年份:2002
- 资助金额:
$ 3.89万 - 项目类别:
Protein Interactions Coordinating Excision Repair and Single-Strand Break Repair
协调切除修复和单链断裂修复的蛋白质相互作用
- 批准号:
8555253 - 财政年份:2001
- 资助金额:
$ 3.89万 - 项目类别:
MACCHESS CONSORTIUM FOR PHASING METHODS IN MACROMOLECULAR CRYSTALLOGRAPHY
MACCHESS 高分子晶体学定相方法联盟
- 批准号:
6491116 - 财政年份:2001
- 资助金额:
$ 3.89万 - 项目类别:
相似海外基金
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
- 批准号:
2400195 - 财政年份:2024
- 资助金额:
$ 3.89万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334970 - 财政年份:2024
- 资助金额:
$ 3.89万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334969 - 财政年份:2024
- 资助金额:
$ 3.89万 - 项目类别:
Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
- 批准号:
23K04919 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
- 批准号:
22KJ2957 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
- 批准号:
23K04494 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
- 批准号:
23K13831 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
- 批准号:
2238379 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
- 批准号:
2154399 - 财政年份:2022
- 资助金额:
$ 3.89万 - 项目类别:
Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
- 批准号:
RGPIN-2019-06633 - 财政年份:2022
- 资助金额:
$ 3.89万 - 项目类别:
Discovery Grants Program - Individual